FIGURE 4.

Effect of NMDA signaling on SULT1A1/3 induction. A, SK-N-MC cells were co-treated with 10 μm NMDA receptor antagonist ketamine (Ket) and 100 μm dopamine (DA) for 24 h. SULT1A1/3 protein levels were quantified by Western blotting. B, cells were co-treated with 10 μm NMDA receptor antagonist ketamine and 100 μm dopamine for 24 h. SULT1A1/3 protein levels were quantified by Western blotting. C, cells were co-treated with 1 μm calcineurin inhibitor cyclosporin A (Cyc) and 100 μm dopamine for 24 h. SULT1A1/3 protein levels were quantified by Western blotting. D, cells were co-treated with 10 μm calcineurin inhibitor FK506 and 100 μm dopamine for 24 h. SULT1A1/3 protein levels were quantified by Western blotting. All results are the mean ± S.E. (error bars), n = 3, normalized to tubulin as loading control and are expressed as percentage of control (C). Asterisks indicate data significantly different (p < 0.05) from control by Student's t test.